Colvin-Galloway Future band
This article was originally published in The Gray Sheet
Executive Summary
U.S. and European launch of the device, which is intended for use in heart valve repair, is announced by Medtronic Oct. 1. Implanted to support the posterior portion of the heart's mitral valve following surgical repair to correct stenosis or regurgitation, the C-G Future is semi-rigid, flexible and low-bulk, and has a profile 20% lower than other available semi-rigid devices, Medtronic claims. More than 90% of patients referred for mitral valve regurgitation underwent repair instead of valve replacement, and 95-99% experienced success, results of a recent study conducted at the Mayo Clinic show. The firm says more than 50,000 surgeries are performed annually worldwide to treat mitral valve insufficiency
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.